These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Constrained corticotropin releasing factor antagonists (astressin analogues) with long duration of action in the rat. Rivier JE; Kirby DA; Lahrichi SL; Corrigan A; Vale WW; Rivier CL J Med Chem; 1999 Aug; 42(16):3175-82. PubMed ID: 10447963 [TBL] [Abstract][Full Text] [Related]
7. Potent, structurally constrained agonists and competitive antagonists of corticotropin-releasing factor. Gulyas J; Rivier C; Perrin M; Koerber SC; Sutton S; Corrigan A; Lahrichi SL; Craig AG; Vale W; Rivier J Proc Natl Acad Sci U S A; 1995 Nov; 92(23):10575-9. PubMed ID: 7479843 [TBL] [Abstract][Full Text] [Related]
8. A single-point slight alteration set as a tool for structure-activity relationship studies of ovine corticotropin releasing factor. Beyermann M; Fechner K; Furkert J; Krause E; Bienert M J Med Chem; 1996 Aug; 39(17):3324-30. PubMed ID: 8765516 [TBL] [Abstract][Full Text] [Related]
12. Binding differences of human and amphibian corticotropin-releasing factor type 1 (CRF(1)) receptors: identification of amino acids mediating high-affinity astressin binding and functional antagonism. Dautzenberg FM; Wille S Regul Pept; 2004 May; 118(3):165-73. PubMed ID: 15003833 [TBL] [Abstract][Full Text] [Related]
13. Structure-activity studies on the corticotropin releasing factor antagonist astressin, leading to a minimal sequence necessary for antagonistic activity. Rijkers DT; Kruijtzer JA; van Oostenbrugge M; Ronken E; den Hartog JA; Liskamp RM Chembiochem; 2004 Mar; 5(3):340-8. PubMed ID: 14997526 [TBL] [Abstract][Full Text] [Related]
14. Characterization of a novel and potent corticotropin-releasing factor antagonist in rats. Menzaghi F; Howard RL; Heinrichs SC; Vale W; Rivier J; Koob GF J Pharmacol Exp Ther; 1994 May; 269(2):564-72. PubMed ID: 8182523 [TBL] [Abstract][Full Text] [Related]
15. Mono- and bicyclic analogs of parathyroid hormone-related protein. 1. Synthesis and biological studies. Bisello A; Nakamoto C; Rosenblatt M; Chorev M Biochemistry; 1997 Mar; 36(11):3293-9. PubMed ID: 9116007 [TBL] [Abstract][Full Text] [Related]
16. Novel high-affinity photoactivatable antagonists of corticotropin-releasing factor (CRF) photoaffinity labeling studies on CRF receptor, type 1 (CRFR1). Bonk I; Rühmann A Eur J Biochem; 2000 May; 267(10):3017-24. PubMed ID: 10806401 [TBL] [Abstract][Full Text] [Related]
17. Stressin1-A, a potent corticotropin releasing factor receptor 1 (CRF1)-selective peptide agonist. Rivier J; Gulyas J; Kunitake K; DiGruccio M; Cantle JP; Perrin MH; Donaldson C; Vaughan J; Million M; Gourcerol G; Adelson DW; Rivier C; Taché Y; Vale W J Med Chem; 2007 Apr; 50(7):1668-74. PubMed ID: 17335188 [TBL] [Abstract][Full Text] [Related]
18. Determinants of corticotropin releasing factor. Receptor selectivity of corticotropin releasing factor related peptides. Mazur AW; Wang F; Tscheiner M; Donnelly E; Isfort RJ J Med Chem; 2004 Jun; 47(13):3450-4. PubMed ID: 15189041 [TBL] [Abstract][Full Text] [Related]
19. Synthesis and relative potencies of new constrained CRF antagonists. Hernandez JF; Kornreich W; Rivier C; Miranda A; Yamamoto G; Andrews J; Taché Y; Vale W; Rivier J J Med Chem; 1993 Oct; 36(20):2860-7. PubMed ID: 8411001 [TBL] [Abstract][Full Text] [Related]
20. Pharmacological comparison of two corticotropin-releasing factor antagonists: in vivo and in vitro studies. Curtis AL; Grigoriadis DE; Page ME; Rivier J; Valentino RJ J Pharmacol Exp Ther; 1994 Jan; 268(1):359-65. PubMed ID: 8301577 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]